WHO Report

Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017

M. Teresa Aguado a, Jane Barratt b, John R. Beard c, Bonnie B. Blomberg d, Wilbur H. Chen e, Julian Hickling f, Terri B. Hyde g, Mark Jit h,i, Rebecca Jones f, Gregory A. Poland j, Martin Friede k,l, Justin R. Ortiz k

# Vaccines and Immunization, Versoix, Switzerland
# International Federation on Ageing, Toronto, Canada
# Ageing and Life Course, World Health Organization, Geneva, Switzerland
# Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA
# Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
# Working In Tandem Ltd, Cambridge, United Kingdom
# Vaccine Introduction Team, Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
# Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, United Kingdom
# Modelling and Economics Unit, Public Health England, London, United Kingdom
# Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN, USA
# Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland

## Abstract

Many industrialized countries have implemented routine immunization policies for older adults, but similar strategies have not been widely implemented in low- and middle-income countries (LMICs). In March 2017, the World Health Organization (WHO) convened a meeting to identify policies and activities to promote access to vaccination of older adults, specifically in LMICs. Participants included academic and industry researchers, funders, civil society organizations, implementers of global health interventions, and stakeholders from developing countries with adult immunization needs. These experts reviewed vaccine performance in older adults, the anticipated impact of adult vaccination programs, and the challenges and opportunities of building or strengthening an adult and older adult immunization platform. Key conclusions of the meeting were that there is a need for discussion of new opportunities for vaccination of all adults as well as for vaccination of older adults, as reflected in the recent shift by WHO to a life-course approach to immunization; that immunization in adults should be viewed in the context of a much broader model based on an individual's abilities rather than chronological age; and that immunization beyond infancy is a global priority that can be successfully integrated with other interventions to promote healthy ageing. As WHO is looking ahead to a global Decade of Healthy Ageing starting in 2020, it will seek to define a roadmap for interdisciplinary collaborations to integrate immunization with improving access to preventive and other healthcare interventions for adults worldwide.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

## 1. Introduction

Vaccination of older adults has been shown to reduce transmission and serious disease caused by vaccine-preventable diseases mainly in high income countries (HIC), but the policy of vaccinating this age group has not been widely implemented in LMICs. The World Health Organization (WHO) convened a meeting in March 2017 to review policies on immunization of adults (with a focus on older adults), to discuss vaccine performance in this group and to review the pipeline of vaccines under development that might be of benefit to adults and older adults in the future. While the meeting was relevant to HICs as well as LMICs, the focus was intentionally on the latter. The only vaccines with WHO recommendations for specific use in elderly adults are influenza vaccines [1], therefore influenza and influenza prevention represented an...
important case study and area of discussion in the meeting for vaccine policy and implementation needs globally. Finally, the meeting aimed to discuss the challenges and opportunities for strengthening adult immunization in LMICs and to identify activities and policies that can be pursued to this end.

This was the first WHO meeting on older adult immunization since 2011 [2]. The objectives of the meeting were the following: (1) to review policies on immunization of adults, with a focus on older adults; (2) to discuss the incidence and determinants of vaccine preventable diseases in adults; (3) to discuss vaccine performance in older adults and the pipeline of vaccines under development that may be of benefit to adults and older adults; (4) to discuss challenges and opportunities for strengthening an adult immunization platform in low- and middle-income countries; and (5) to identify policies that could be developed and activities that can be pursued to promote access to vaccination for older adults in LMICs. Participants included academic and industry researchers, funders, civil society organizations, implementers of global health interventions, and stakeholders from developing countries with adult immunization needs. The agenda and list of participants are in the Online Supplement. The two-day meeting was organized around a series of background topic areas, followed by case studies in LMICs, and then discussion on data needs for policies and investments of vaccine programs targeting older adults. This report is based on presentations and discussion from the meeting.

2. Ageing and vaccination

2.1. Changing demographics and markets for vaccines

The world population is ageing. The number of individuals aged 60 and older is predicted to increase from 600 million to 2 billion from 2000 to 2050, with 80% of older adults living in developing regions [3], with a preponderance of women [4]. As people age, they develop increased susceptibility to many infectious diseases. As part of a broad public health strategy the number of vaccine doses needed to target older adults is anticipated to outpace those needed by routine pediatric immunization programs.

Some countries are developing plans for this demographic change, but many countries do not have vaccination policies specifically targeting adult populations. Even in HICs, vaccination use in adults can be low [5]; for example, despite a WHO recommendation, only 45% of 115 member states with an influenza policy include programs targeting the “elderly” risk group, and most of these are HICs [6].

For the purposes of this report, older adults are defined as people in the second half of their life, i.e. over half of the life expectancy for a particular country. While examples and discussion specific to older adults are provided in this report, sometimes when the data specific to older adults are sparse or when discussion of a broader age group is warranted, the report refers to all adults.

2.2. WHO vaccine recommendations and age

Current WHO guidance on routine vaccines, summarized in WHO vaccine position papers [7], focuses heavily on pediatric immunization. There is some consideration of immunization in pregnancy, immunization in health-care workers, high-risk occupations, notes on travel vaccines or regional use, but few recommendations for vaccination to protect adults in general against infectious diseases, with the exception of a permissive recommendation for influenza vaccine use in elderly persons and persons with chronic disease. The older target group is not defined by WHO, and countries have implemented “elderly” influenza vaccine programs beginning at a variety of ages (including 50, 60, and 65 years).

WHO has a mandate within the Global Vaccine Action Plan 2011–2020 to “improve health by extending by 2020 and beyond the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live” [8]. Furthermore, the WHO Initiative for Vaccine Research (IVR) has long been interested in immunization of older adults, and has held and contributed to relevant meetings on the topic over the past decade [2], which have influenced the research agenda worldwide. Of the major data gaps previously identified, most still remain [2]. These include disease burden data for many vaccine preventable diseases in older adults, duration of protection of routine childhood vaccines among older adults, performance of new vaccines targeting older adults within LMIC contexts, and how to identify the optimal time for immunization of older adults to ensure sufficient immunologic response and memory.

One goal in the WHO’s Global Strategy and Action Plan on Ageing and Health [9] is to design interventions to prevent disease and to influence trajectories of individuals' intrinsic capacity (defined as a combination of one's physical and mental capacities). One of the important activities to promote healthy ageing is to “ensure access and affordability of medical products, vaccines, and technologies” as part of integrated care for people in the second half of life [10].

2.3. Definitions: at what age are people considered old?

Healthy ageing is defined by the WHO as “the process of developing and maintaining the functional ability that enables wellbeing in older age” [11]. This ability depends on both an individual’s physical and mental capacities and on the environments one inhabits.
programs targeting them. There are more limited data on other ease in older adults and the unrealized potential impact of vaccine observed with influenza vaccination in Japan [23] and the United similar studies have been conducted in Central America manufactured influenza vaccines to high-risk older adults. This finding led to a policy of administering domestically-correlated with hospital admissions and deaths in older adults. It has been suggested that a highly effective infant influenza vaccination program might make vaccinating older infants unnecessary [25], but further data are necessary. Another vaccine example is the a substantial positive impact of pneumococcal vaccination of infants and children on mortality and morbidity of seniors which was observed in the United States [26]. Another benefit of vaccinating people of all ages is an indirect effect on the ability of microbes to resist the effects of drugs, or anti-microbial resistance (AMR). The Global Action Plan on AMR [27] states that immunization could reduce AMR in three ways: first, by using existing vaccines to prevent infectious diseases whose treatment would require antimicrobials; second, by using existing vaccines to reduce the prevalence of primary viral infections which are often inappropriately treated with antibiotics or that can lead to secondary infections that require antibiotic treatment; and, third, by the development and use of new vaccines targeting pathogens difficult to treat (or untreatable) due to AMR. In addition, vaccination might selectively target resistant strains of an organism, reduce the opportunity for pathogens to exchange resistance genes, or reduce bystander selection of resistance in normal flora species [29]. Several studies illustrate how existing vaccines can reduce infections in vaccinees of all ages [30] and through population (herd) immunity [31], but very few studies have been conducted to measure vaccine effectiveness at preventing anti-microbial use or AMR. As secondary outcomes of pneumococcal conjugate vaccine (PCV) use, some studies in infants in HICs have shown a reduction in antibiotic prescription [32], a reduction in antimicrobial purchases [33], or reduced duration of antibiotic use [34]. Modeling studies have concluded that high coverage with PCV in 75 countries not currently achieving 80% coverage could avert many millions of days of antibiotic use in young children [35]. Low-income countries (LICs) are at highest risk of AMR [36], so vaccine use in those countries could potentially yield the greatest benefits. There is, however, a significant lack of data on the impact of vaccines on AMR in LICs, especially in older adults.

3.3. Health economics of vaccination of adults and older adults

Health economic evaluations such as cost-effectiveness analysis are important tools for investigating whether the social and economic benefits of an intervention such as vaccination outweigh the opportunity costs of the intervention. However, evaluations of vaccination of adults and older adults in LMICs are severely lacking compared to similar evaluations of pediatric vaccination. For example, two reviews of cost-effectiveness studies of seasonal influenza vaccination found only five studies for older adults in LMICs [37,38]. Many economic evaluations do not capture some of the broader economic benefits of vaccination at the individual, household and society level that are particularly relevant to adult vaccination. For example, evaluations of the indirect benefits of vaccination should consider the roles older adults play in the volunteer sector and as caregivers in families and communities, looking after infants and children as part of the “informal economy” [39]. These aspects may be particularly valuable in LMICs [40]. In addition, traditional measures of health utility such as quality- or disability-adjusted life years may not capture what older adults value most about good health and maintenance of functional ability. Alternative measures of health utility for older adults have been proposed, including independence, and ability to do the things that they value [41]. The impact of population (herd) immunity adds a further level of complexity to economic evaluations. In some settings, it might be more cost-effective to protect older adults from an infection by vaccinating infants to eliminate the infant reservoir of the pathogen. Consensus guidelines for methodological approaches to estimating direct and indirect costs of vaccine-preventable diseases in LMICs are required, and are being developed by WHO for influenza [42]. Similar guidance would be of value for other vaccine preventable diseases that disproportionately affect older adults.

Please cite this article in press as: Teresa Aguado M et al. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029
4. Protection of older adults

4.1. Vaccine performance in older adults

Vaccine performance can be measured by vaccine immunogenicity, efficacy, or effectiveness. Vaccines can be less immunogenic in older adults due to immunosenescence (see Section 4.2). Concomitant anti-inflammatory and immunomodulatory therapies are more likely to have significant negative interactions with vaccines in older adults [43]. Immune responses (and adverse reactions) to vaccines tend to be higher in females than males, and loss of function with age might be more frequent or of greater magnitude in males [4]. At all ages, vaccine effectiveness tends to be higher in women than in men [4].

Often vaccines have a lower vaccine effectiveness in older adults compared to younger adults, and several approaches have been used to overcome this: (a) increasing the number of doses administered, (b) increasing the dose of antigen in the formulation, and (c) incorporating adjuvants, such as MF59 in the Fludar® seasonal influenza vaccine [44]. It has been proposed that early-season use of influenza vaccines might result in antibodies that wane by the start of a late-season virus circulation [45] so the timing of vaccination could also be important.

The performance of seasonal influenza vaccines in older adults has been reviewed in several meta-analyses [46,47], and vaccine effectiveness has been observed to be suboptimal compared to other age groups. However, recent systematic reviews of the use of adjuvanted influenza vaccine formulations [44] and intradermal administration [47] have shown improved immunogenicity of seasonal influenza vaccines in the elderly. These studies have been conducted in HICs and less data are available on influenza vaccine use in adults in LMICs [48]. PCV and pneumococcal polysaccharide vaccine (PPV) effectiveness have also been reviewed; PPV effectiveness was found to be 50% [30] and PCV effectiveness was 48.5% in preventing invasive pneumococcal disease in healthy adults aged 65 years and over [49].

Analyses have shown that the high-dose influenza vaccine in older adults (Fluzone®, Sanofi Pasteur) performs better in older adults than the standard influenza vaccines [50]. It has a higher VE, and induces higher antibody responses in adults aged more than 65 years compared with the standard formulation (60 μg HA vs 15 μg HA per dose). A supplementary analysis showed the high-dose vaccine was better at preventing serious cardiorespiratory events and pneumonia than the standard vaccine [51], and a retrospective cohort study in the United States found the vaccine to be more effective than the standard dose vaccine.
in preventing influenza-related medical encounters, hospital admissions, and death in adults 65 years of age and older [52–54].

4.2. Immunosenescence and biomarkers

Studies of immunosenescence in preclinical models and humans have identified many aspects of adaptive and innate immune responses that decline or change with age [55]. Biomarkers for these changes have the potential to inform more rapid vaccine development for older adults. The number of naïve T lymphocytes declines with age, following involution of the thymus after puberty, compromising the ability to respond to new vaccinations (or infections). It has also been suggested that the expanded T cell responses required to keep persistent infections controlled, such as Epstein Barr virus and human cytomegalovirus (HCMV), reduces “space” for new T cells, particularly CD8+ T cells [55]; however, the effect of HCMV infection on immune function, including the response to influenza vaccine, appears to be heterogeneous, and is seen only in older individuals who might have had persistent HCMV infection for decades [56]. Recently, older adults were shown to have increased senescent and exhausted variella zoster virus (VZV)-specific T cells which may contribute to their inability to prevent VZV reactivation and the subsequent development of herpes zoster [57].

The number and function of B lymphocytes also decreases with age, with an increase in the number of late/exhausted B cells that are terminally differentiated, non-proliferating and with poor effector function [58,59]. Many immune cell types express a senescence-associated secretory phenotype, defined as the secretion of several pro-inflammatory cytokines including tumor necrosis factor alpha, interleukin 6 and interleukin 8 [55,58], which promotes chronic low-grade inflammation. Numbers of dendritic cells (DCs) and Langerhans cells decline [60], and DCs exhibit reduced phagocytosis and class 1 human leucocyte antigen expression [55].

These changes in immune function have been shown to impair primary responses to yellow fever (YF) vaccine in travelers, even though protective levels were still achieved [60]. Memory immune responses, such as to seasonal influenza vaccine, have also been shown to be affected [58].

Despite immunosenescence, it is still possible to induce immune responses in older adults that are protective or equivalent to those seen in younger age groups; examples include: (a) phase III trials of the two-dose HZ/Su subunit vaccine branded as “Shingrix” against herpes zoster that showed similar vaccine efficacy in ages 50 years and older [61] and 70 years and older (~90%) [62]; (b) phase I/II trial of a candidate *Staphylococcus aureus* single dose, non-adjuvanted, inactivated vaccine in healthy adults aged 65–85 years showed that functional antibody responses which met pre-defined thresholds in the older adults [63]; and (c) two trials with different *Clostridium difficile* vaccines that showed similar responses across different age groups [64,65].

Identification of biomarkers of immunosenescence might inform rational design of vaccines, for example those that include novel adjuvants, to enhance immune responses in older adults, or could be used to identify individuals who are unlikely to respond to a given vaccine. Systems approaches in biology research are being used to identify such markers [66]. Data obtained to date suggest that the changes observed in immunosenescence are also found in many fundamental biological pathways such as cell proliferation and hormone regulation as well as lymphocyte activation and differentiation [66].

Although most of the data on ageing and immunosenescence have been collected in HICs, a pilot study conducted in Pakistan found similar changes in immune cell phenotypes in young (aged 18–28 years) and older (aged 50–85 years) men, to those seen in HICs [67].

5. Vaccines that are or could be of benefit to older adults

Multiple licensed vaccines are currently used in adults, although they remain underused in the general adult population and in some target groups. In addition, there are new vaccines for adults in the development pipelines of many vaccine manufacturers (Table 2).

Some of the vaccines in Table 2 are of interest for people of any age with low intrinsic capacity, such as *Staphylococcus aureus* [68]; extraintestinal pathogenic *Escherichia coli*, because of its role in urinary tract infections [69]; and *C. difficile*, because of its high morbidity and mortality, especially in older adults. These three pathogens are also important targets from the perspective of reducing AMR.

6. Considerations for vaccination of adults and older adults in LMICs

As stated above, much of the data on the need for, and use of, vaccines for adults comes from studies in HICs. There are, however, important differences between HIC and LMICs that need to be taken into consideration, including specifics related to adult immunization in terms of disease epidemiology, health infrastructure, opportunities for life-course immunization, and policymaking in this age group.

6.1. Disease epidemiology and comorbidities

The epidemiology and timing of infectious diseases can be very different in LMICs, based on factors such as differential exposure due to climate, geography and hygiene and an earlier risk of exposure to a diverse and larger number of pathogens. In addition, coinfections such as tuberculosis or human immunodeficiency virus (HIV) can affect the risk of severe outcomes from vaccine-preventable diseases as well as the immune response to vaccines [70]. Immune responsiveness can also be affected by differences in nutrition, such as vitamin A deficiency [71], and obesity [72]. There is also evidence, albeit in infants, that diet, exposure to microorganisms and parasites, and anti-microbial (and anti-

### Table 2

Examples of licensed vaccines, or vaccines in development, for use in adults– by stage of development, as of 2017.

| Stage          | Vaccines                                                                 |
|----------------|--------------------------------------------------------------------------|
| Preclinical    | Influenza, Respiratory syncytial virus                                   |
| Phase I        | *Clostridium difficile*, HIV, Respiratory syncytial virus                |
| Phase II       | *E. coli, Enterotoxigenic Escherichia coli*, Extra-intestinal pathogens  |
|                | *Escherichia coli*, HIV, *Norovirus*, Respiratory syncytial virus,       |
|                | *Staphylococcus aureus*, Streptococcus pneumoniae* (pneumococci)         |
| Phase III      | *Clostridium difficile*, *V. zoster* virus                               |
| Licensed       | *Diphtheria* pertussis, *Hepatitis A* virus, *Hepatitis B* virus,       |
|                | *influenza meningococcal meningitis*, pneumococci, *V. zoster* virus,    |
|                | *Haemophilus influenzae* type b                                           |
| Not publicly   | Group B streptococcus, *Z. f. virus*                                    |

Notes: Vaccines exclusively for maternal immunization to protect newborns and cancer immunotherapies have not been included. Vaccines for pathogens in bold were discussed at the WHO Product Development for Vaccines Advisory Committee 2016 meeting; references are on the meeting website [96]. See also the WHO Vaccine Pipeline Tracker [97] for references for dendr, *E. coli, enteric* diseases, HIV, malaria, *Mycobacterium tuberculosis*, Respiratory syncytial virus, *Z. f. virus* and other priority emerging pathogens and WHO information on vaccines and diseases for landscape analyses [98].
helminthic) use can affect the immune system [73]. In general, there may be a myriad of environmental conditions that result in a different picture of co-morbidities of infectious diseases and other non-communicable diseases (NCDs) and conditions in LMICs compared with HICs. Reduced access to healthcare and social services in LMICs can also affect an individual’s functional capacity at any age, and can limit access to vaccination.

6.2. Health infrastructure for adult vaccination

The implementation in 1974 of the Expanded Programme on Immunization (EPI) has meant that routine immunization infrastructure has focused on neonates, infants (e.g. immunization visits at ages 6, 10 and 14 weeks, and 9 months) and pregnant women. Achieving high vaccination coverage in target groups outside the traditional program can be difficult. Countries considering strengthening immunization platforms for older adults would benefit from strategies and lessons learned from similar efforts in other age groups [74]. Currently, more than 80 countries have introduced human papillomavirus (HPV) vaccine into their national immunization programs, usually with school-based vaccination; 33 of these are LMICs, and an additional 25 LMICs are undertaking pilot programs prior to full scale introduction [75]. Lessons learned from HPV programs [76], including the usefulness of pilots or demonstration projects [77], could be valuable for establishing new platforms for adult vaccines, especially ones where multi-dose regimens are required [78]. For example, adults taking infants to a pediatric vaccination clinic could also be offered immunizations or other services.

6.3. Opportunities within life-course immunization in LMICs

A major barrier in many LMICs is that there is often not a comprehensive health system to reach all adults, including older adults, for preventive healthcare. If one could be established, it could have many benefits for all kinds of health interventions, including screening, diagnostics and treatments.

There is interest within the vaccine community, and those whose primary focus is the health of older adults in general, on new opportunities to build preventive and other healthcare services around or including immunization. Life-course immunization may include the following healthcare points and systems: well-baby, school-entry, school-leaving, general practice, community pharmacies [79], community nurses, adolescent health, universities and colleges, ante-natal care, outpatient clinics for the chronically sick, nursing homes, military services, services for new migrants, and travel vaccination clinics.

Many healthcare systems may benefit from increasing attention on disease prevention, particularly in LMICs. Increasingly, there is anticipated to be a shift to self-management of and prevention of medical conditions, with individuals taking more responsibility for their health, which could include demanding vaccines for themselves or their parents or other family members.

6.4. Mandates and policymaking

Although adults and older adults are not often explicitly identified as target groups for vaccination, they are included in global strategies and policies. The stated vision of the Decade of Vaccines (2011–2020) is for “a world in which all individuals and communities enjoy lives free from vaccine-preventable disease” [8]. In addition, Goal 3 of the United Nations Sustainable Development Goals [80] is to “ensure healthy lives and promote well-being for all at all ages”, and includes a target of “access to safe, effective, quality and affordable essential medicines and vaccines for all”. Despite broad, bold policy statements, however, there is often delayed uptake of new vaccines for some target groups and ages for a variety of reasons [81], some of which are especially applicable to adult vaccination. For example, successful introduction of any new vaccine requires engagement and alignment of multiple stakeholders. Governments must see the value in a new vaccine before they are willing to introduce it and this requires recognition of the burden of disease and the fact that an affordable, deliverable vaccine is available. Purchasers (donors, governments or private health providers) are unlikely to pay for the vaccine unless they think it will be seen as a priority by end users, and vaccine developers and manufacturers will not produce the vaccine unless they believe it will be purchased. Other reasons relate to the general lack of awareness by adults that vaccine-preventable diseases such as pneumococcal pneumonia, influenza and shingles can have devastating effects on the health, function and socioeconomic contributions of a normal healthy older person, let alone those who may have a chronic condition such as diabetes.

To promote influenza vaccination of older adults, for example, it might be important to recognize that seasonal influenza infections do not just result in a short-term increase in accelerated mortality, but also result in low-quality of life and morbidity that can extend for several months after the influenza season [82]. The costs of the social and economic burden need to be quantified for the stakeholders in question. In some situations, to stimulate uptake of vaccines for an ageing population, it might be preferable to re-frame the narrative to one that reflects the contributions that older adults across society make with advancing age in good health or simply their higher quality of life.

7. Barriers to adult vaccination

Adult vaccine coverage is low, even in HICs, for a variety of reasons [83]. Perceived and actual barriers can be categorized at the level of the individual and community demand for vaccines, or with the vaccination process and system (Table 3). This list of barriers has been modified from a prior publication [79], with additional information based on presentations and discussion at the meeting. Some of the barriers apply to vaccination of all age groups; others are specific or more relevant to vaccination of adults.

Despite the barriers to vaccination after infancy, some which are listed in Table 3, many countries are gaining experiences that should be useful in the future and to other countries [84]. The International Federation on Ageing’s World Coalition on Adult Vaccines [85] is one of several global and regional projects aiming to help improve uptake rates of adult vaccination through building an understanding of the community and systemic barriers and then working across sectors and disciplines to create solutions.

8. Gaps in knowledge

One of the objectives of the meeting was to identify challenges and opportunities for strengthening adult immunization in LMICs. Significant gaps in knowledge regarding vaccination of adults and older adults, particularly in LMICs, were identified (Table 4). Most of the existing data that are available come from HICs, or a limited number of MICs (Brazil, China, India, Mexico, Thailand). Some MICs have parts of their population with some characteristics of HIC and other parts that are under-developed. They could represent good settings to compare interventions in different subpopulations of the same country exposed to different conditions.
Notes. The list is modified from [79]. The focus on barriers and responses for adult vaccination was gathered from presentations and discussion at the meeting.

Table 4

Gaps in knowledge supporting decision-making for adult and older adult immunization in developing countries.

| Gap in Knowledge | Comments |
|------------------|----------|
| **Burden of disease** | Encourage gathering and sharing of data on broad measures of health (not just deaths due to disease); consider exacerbation of co-morbidities such as cardiovascular disease and chronic obstructive pulmonary disease |
| What is the true burden of disease for infections that might be preventable in adults and older adults, especially in low- and middle-income countries (LMICs)? | Large, long-term cohort studies are required to evaluate the impact of vaccine preventable diseases (and of vaccination) on frailty and relevant measures of quality of life, health care expenditure and wider social costs |
| What are the broader impacts of vaccine-preventable diseases in older adults? | NCD endpoints (including frailty) could be incorporated in vaccine trials, using measures appropriate for LMICs. Observational studies could also be informative |
| **Benefits of immunization for adults and older adults** | As well as standard measures, there is a need to determine how to measure the economic value of adults at different ages, including in informal economy (e.g. caregivers). It is important to assess indirect economic value by preventing disease and disability, as well as by preventing exacerbation of existing co-morbidities. Patient and household surveys can help to identify the socioeconomic contribution of older adults |
| Are there associations or causal links between infectious disease and non-communicable diseases (NCDs), and what is the impact of vaccination including in older adults? | With sufficient baseline data, reduction in antibiotic use could be used as an endpoint in clinical studies of vaccines |
| What are the broader economic benefits of vaccination in older adults? | Systems approaches could be applied to studying the biology of immunosenescence [103] |
| What data are available the impact of adult vaccines on anti-microbial use in LMICs? | Different populations in high-income countries (HICs) and LMICs and with different co-morbidities should be compared |
| **Immune responses in adults and older adults** | As an example, the response to influenza vaccines in people taking statins is altered and may be lower [104,105] |
| How does immune function change with ageing? Is the process of immunological ageing the same in HICs and LMICs? | (continued on next page) |
9. Conclusions

There are global mandates to expand and strengthen immunization in older adults, however critical data to inform policy making and public health practice in LMICs remain limited. More data are needed on vaccine-preventable disease burden in older adults in LMICs and the estimated impact vaccines would have on this burden. Further, new ways to look at impact of vaccine programs, that take into account the contributions of healthy older adults and the consequences of their declining intrinsic capacities to society, are needed. Two clear conclusions from the meeting were that immunization of adults should be viewed as a key component of a comprehensive approach to health, and that protecting older adults from vaccine-preventable diseases might mean achieving high vaccine coverage in all age groups (including infants), and not simply older adults. Additionally, the need for vaccine research and development related to immunosenescence was identified, given the remarkable increase in the population of older adults.

To achieve significant increases in adult vaccination coverage, the knowledge gaps listed in Table 4 should be addressed. Equally important will be the need for a shift in overall thinking about providing protection against vaccine-preventable diseases, which has to date focused nearly exclusively on vaccination of infants [86]. Activities to improve coverage with infant vaccines should not diminish, but an increasing emphasis needs to be placed on life-course approach to immunization schedules to protect adults and older adults, especially given the significant and changing demographics of the global population. There is already some evidence from HICs of the benefits of using existing vaccines in older adults [49,82]. Although the efficacy of some vaccines might be lower in older adults than is usually seen with infant vaccines, these data need to be viewed in the context of the increased risks from disease and broader social and economic benefits of prevention in older populations. Misconceptions about the benefits of vaccination of older adults should not prevent its use.

Decreasing adult preventable disease through improved uptake of appropriate vaccines will require strong champions, both individual and institutional [87], at a time when there are many competing priorities for health spending. Obtaining data is critical to gaining a deeper understanding of the impact of adult vaccination on problems such as AMR, as well as the growing need to guard against preventable illnesses in an ageing global population with co-morbidities and concomitant conditions. The “business case,” that is, the direct and indirect associated health-care and broader societal costs and benefits, is critical to justify a life-course approach to vaccination. Raising awareness of the importance of vaccination of adults and older adults is just the beginning of truly cementing the intervention within a broader public health strategy.

Disclaimer

Martin Friede and Justin R. Ortiz are employees of the World Health Organization. Terri B. Hyde is an employee of the US Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the World Health Organization and the US Centers for Disease Control and Prevention.

Acknowledgements

We acknowledge Chiara Gerardi, Marc Perut, and Sonia Sahraoui for their contributions to organizing the meeting. We also thank Angela Hwang for editorial advice.

Financial support

The authors acknowledge the contributions of the US Centers for Disease Control and Prevention (CK14-1402), which provides financial support to the World Health Organization Initiative for Vaccine Research. The authors also acknowledge contributions of the US National Institutes of Health (U01AI108543-01), which provided grant funding for partial support of this meeting.

Potential conflicts of interest

1. M. Teresa Aguado: None to declare.
2. Jane Barratt: None to declare.
3. John R. Beard: None to declare.
4. Bonnie B. Blomberg: Dr. Blomberg has served as a consultant to Novavax.
5. Wilbur H. Chen: Dr. Chen has served as a consultant to MedImmune and GSK.
6. Martin Friede: None to declare.
7. Julian Hickling: Working in Tandem receives consultancy fees from Vaxxas Pty Ltd.
8. Terri B. Hyde: None to declare.
9. Mark Jit: None to declare.
10. Rebecca Jones: Working in Tandem receives consultancy fees from Vaxxas Pty Ltd.
11. Justin R. Ortiz: None to declare.
12. Gregory A. Poland: Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Dynavax, Novartis Vaccines and Therapeutics, Seqirus, and Adjuvance Technologies. Dr. Poland holds three patents related to vaccinia and measles peptide vaccine research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.

References

[1] World Health Organization. Vaccines against influenza WHO position paper - November 2012. Repeve epidemiologické hebdomadári, 2012/12/06 ed2012. p. 461–76.
[2] Thomas-Crusells J, McElhaney JE, Aguado MT. Report of the ad-hoc Pileggi C, Mascaro V, Bianco A, Nobile CGA, Pavia M. Immunogenicity and.
[3] Hirve S, Krishnan A, Dawood FS, Lele P, Saha S, Rai S, et al. Incidence of influenza-associated hospitalization in rural communities in western and northern India, 2010–2012: a multi-site population-based study. J Infect 2015; 70:160–70.
[4] Piralam B, Tomczyk SM, Rhodes JC, Thamthiwat S, Gregory CJ, Olsen SJ, et al. Incidence of pneumococcal pneumonia among adults in rural Thailand, 2006–2011: implications for pneumococcal vaccine considerations. Am J Trop Med Hyg 2015;93:1140–7.
[5] Behfar TA, Sogaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344:889–96.
[6] Cohen SA, Chui KKH, Naumova EN. Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002–2006. J Am Geriatr Soc 2011:59:327–32.
[7] Hodgson D, Baguelin M, van Leeuwen E, Panovska-Griffiths J, Ramsay M, Pebody R, et al. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis. Lancet Public Health 2017;2:e74–81.
[8] Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs); 2017.
[9] World Health Organization. Global action plan on antimicrobial resistance; 2015.
[10] Kwong JC, Maaten S, Upshur REG, Patrick DM, Marra F. The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis 2009;49:750–6.
[11] Lipsitch M, Siber GR. How can vaccines contribute to solving the antimicrobial resistance problem? Mbio 2016;7.
[12] Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1144–52.
[13] Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2001;344:1543–6.
[14] Fireman B, Black SB, Shingley HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003;22:10–6.
[15] Dagan R, Sikuler-Cohen M, Zamir O, Jano J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees, Pediatr Infect Dis J 2001;20:951–8.
[16] Jit M, Lassig AA, Jokubonis P, Newbold C, Parboosingh J, Paes et al. Effect of pneumococcal Haemophilus influenzae type B conjugate vaccine (PCV-10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. Lancet Infect Dis 2014;14:205–12.
[17] LaRussac R, Matson F, Horn S, Bower C, Rutteridge A, Klugman K, et al. Access to effective antimicrobials: a worldwide challenge. Lancet 2016;387:168–75.
[18] Padget M, Guillenot D, Delaroque-Astagneau E. Measuring antibiotic consumption in low-income countries: a systematic review and integrative approach, Int J Antimicrob Agents 2016;48:27–32.
[19] Ott J, Klein Breteler J, Tam JS, van der Putten IM, Evers SMAA, Deogaonkar R, Jit M, Hutubessy RCW. Influenza cost and cost-effectiveness studies globally—a review. Vaccine 2013;31:5139–48.
[20] Jit M, Hutubessy R, Peg ME, Sundaram N, Audimulam J, Salim S, et al. The broader economic impact of vaccination: an assessment of vaccine effectiveness in low- and middle-income countries. Vaccine 2012;30:4819–25.
[21] McManus Z, Bingham CO. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in people with rheumatic diseases. Arthritis Res Ther 2014;16:209.
[22] van der Putten IM, Evers SMAA, Deogaonkar R, Jit M, Hutubessy RCW. Staphylococcus aureus infections in long-term care facilities: an ecological study. Clin Infect Dis 2009;49:627–34.
[23] Flynn TN, Chan P, Coast J, Peters TJ. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. Appl Health Econ Health Pol 2011;9:317–29.
[24] de Francisco Shapovalova N, Donadel M, Jit M, Hutubessy R. A systematic review of the social and economic burden of influenza in low- and middle-income countries. Vaccine 2015;33:6537–44.
[25] McMahan Z, Bingham CO. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther 2014;16:506.
[26] Donnheim A, Arata L, Amuciza D, Puig-Barberà J, Gasparini R, Fanfani D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine 2017;35:513–20.
[27] Radin JM, Hawkwsworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010–2013 until 2013–2014. Vaccine 2016;34:3907–12.
[28] Darwishian M, van den Heuvel ER, Bissielo A, Castillo J, Cohen E, Englund H, et al. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. Lancet Respir Med 2017;5:200–11.
[29] Pfelegi C, Mascaro V, Bianco A, Nobile CGA, Pavia M. Immunogenicity and safety of intradermal influenza vaccine in the elderly: a meta-analysis of randomized controlled trials. Drugs Aging 2015;32:857–69.

Please cite this article in press as: Teresa Aguado M et al. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029
[105] Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. J Infect Dis 2016;213:1216–23.

[106] McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015;135:331–43.

[107] Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500–7.